JPWO2021216385A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2021216385A5 JPWO2021216385A5 JP2022563894A JP2022563894A JPWO2021216385A5 JP WO2021216385 A5 JPWO2021216385 A5 JP WO2021216385A5 JP 2022563894 A JP2022563894 A JP 2022563894A JP 2022563894 A JP2022563894 A JP 2022563894A JP WO2021216385 A5 JPWO2021216385 A5 JP WO2021216385A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition comprises
- atazanavir
- cycloprolylglycine
- artemether
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (13)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063012432P | 2020-04-20 | 2020-04-20 | |
| US63/012,432 | 2020-04-20 | ||
| US202063018768P | 2020-05-01 | 2020-05-01 | |
| US63/018,768 | 2020-05-01 | ||
| US202063032116P | 2020-05-29 | 2020-05-29 | |
| US63/032,116 | 2020-05-29 | ||
| US202063037373P | 2020-06-10 | 2020-06-10 | |
| US63/037,373 | 2020-06-10 | ||
| US202063041812P | 2020-06-19 | 2020-06-19 | |
| US63/041,812 | 2020-06-19 | ||
| US202163170350P | 2021-04-02 | 2021-04-02 | |
| US63/170,350 | 2021-04-02 | ||
| PCT/US2021/027848 WO2021216385A1 (en) | 2020-04-20 | 2021-04-17 | Methods for the prophylaxis and treatment of covid and covid-19 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023526754A JP2023526754A (ja) | 2023-06-23 |
| JPWO2021216385A5 true JPWO2021216385A5 (https=) | 2024-04-30 |
| JP2023526754A5 JP2023526754A5 (https=) | 2024-04-30 |
Family
ID=78270185
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022563894A Pending JP2023526754A (ja) | 2020-04-20 | 2021-04-17 | Ｃｏｖｉｄ および ｃｏｖｉｄ－１９ の予防と治療の方法 |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US12239629B2 (https=) |
| EP (1) | EP4138906A4 (https=) |
| JP (1) | JP2023526754A (https=) |
| AU (1) | AU2021259185A1 (https=) |
| BR (1) | BR112022021304A2 (https=) |
| CA (1) | CA3179317A1 (https=) |
| GB (3) | GB2632086A (https=) |
| WO (1) | WO2021216385A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2021216385A1 (en) | 2020-04-20 | 2021-10-28 | Tran Lloyd Hung Loi | Methods for the prophylaxis and treatment of covid and covid-19 |
| BR112022022243A2 (pt) * | 2020-05-01 | 2022-12-20 | Yissum Res Dev Co Of Hebrew Univ Jerusalem Ltd | Bloqueadores do canal de proteína e e inibidores de orf3 como agentes anti-covid-19. |
| JP2024538711A (ja) * | 2021-10-06 | 2024-10-23 | メディエンス カンパニー リミテッド | エファビレンツ及びフルオキセチンを有効成分として含有するウイルス感染症の予防又は治療用薬学的組成物 |
| EP4427740A4 (en) * | 2021-11-05 | 2025-10-22 | G2Gbio Inc | PHARMACEUTICAL KIT FOR PARENTERAL CO-ADMINISTRATION |
| US20250025473A1 (en) * | 2021-11-12 | 2025-01-23 | Albert Einstein College Of Medicine | Cell impermeable kinase inhibitors to treat sars-cov-2 and/or hsv viral infections |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2002340465A1 (en) | 2001-11-09 | 2003-05-19 | Neuronz Biosciences, Inc. | Cyclo(prolyl-glycine) and methods of use to treat neural disorders |
| US7232798B2 (en) | 2001-11-13 | 2007-06-19 | Tran Loi H | Neuroprotection and neuroegenisis by administering cyclic prolyl glycine |
| US7842719B2 (en) * | 2002-10-31 | 2010-11-30 | Kemin Foods, L.C. | Use of endoperoxides for the treatment of infections caused by flaviviridae, including hepatitis C, bovine viral diarrhea and classical swine fever virus |
| EP4368202A3 (en) | 2007-03-30 | 2024-08-21 | The Research Foundation for The State University of New York | Attenuated viruses useful for vaccines |
| AU2008287542C1 (en) * | 2007-06-01 | 2015-01-22 | The Trustees Of Princeton University | Treatment of viral infections by modulation of host cell metabolic pathways |
| CN112423774A (zh) | 2018-05-15 | 2021-02-26 | L·H·L·特兰 | 用于治疗轻度认知障碍、抑郁和心理障碍的治疗剂组成及使用方法 |
| US10980756B1 (en) * | 2020-03-16 | 2021-04-20 | First Wave Bio, Inc. | Methods of treatment |
| WO2021209740A1 (en) * | 2020-04-16 | 2021-10-21 | Mereo Biopharma 4 Limited | Methods involving neutrophil elastase inhibitor alvelestat for treating coronavirus infection |
| WO2021216385A1 (en) | 2020-04-20 | 2021-10-28 | Tran Lloyd Hung Loi | Methods for the prophylaxis and treatment of covid and covid-19 |
| CN111803491A (zh) * | 2020-07-24 | 2020-10-23 | 中国人民解放军军事科学院军事医学研究院 | 青蒿素类化合物在治疗冠状病毒感染方面的应用 |
| CN114246858A (zh) * | 2020-09-21 | 2022-03-29 | 北京化工大学 | 青蒿素类化合物在治疗和预防冠状病毒感染中的应用 |
-
2021
- 2021-04-17 WO PCT/US2021/027848 patent/WO2021216385A1/en not_active Ceased
- 2021-04-17 GB GB2416046.7A patent/GB2632086A/en active Pending
- 2021-04-17 GB GB2217355.3A patent/GB2613460B/en active Active
- 2021-04-17 CA CA3179317A patent/CA3179317A1/en not_active Abandoned
- 2021-04-17 AU AU2021259185A patent/AU2021259185A1/en not_active Abandoned
- 2021-04-17 EP EP21793162.5A patent/EP4138906A4/en active Pending
- 2021-04-17 JP JP2022563894A patent/JP2023526754A/ja active Pending
- 2021-04-17 BR BR112022021304A patent/BR112022021304A2/pt not_active Application Discontinuation
-
2022
- 2022-10-18 US US18/047,432 patent/US12239629B2/en active Active
-
2024
- 2024-11-01 GB GBGB2416189.5A patent/GB202416189D0/en active Pending
-
2025
- 2025-01-25 US US19/037,137 patent/US20250319060A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK168514B1 (da) | Synergistisk produkt indeholdende en kombination af amantadin og selegilin, fremgangsmåde til fremstilling af produktet og anvendelse af amantadin og selegilin til fremstilling af produktet | |
| US20080096832A1 (en) | Method for Improving the Pharmacokinetics of an NNRTI | |
| WO2005065069A3 (en) | Pharmaceutical methods, dosing regimes and dosage forms for the treatment of alzheimer's disease | |
| GB2613460A (en) | Methods for the prophylaxis and treatment of Covid and Covid-19 | |
| DK166479B (da) | Anvendelse af fluoxetin, norfluoxetin eller et farmaceutisk acceptabelt salt af fluoxetin eller norfluoxetin til fremstilling af et laegemiddel med anxiolytisk virkning | |
| KR20070042917A (ko) | 소아 천식의 치료 | |
| CN1805729A (zh) | 鼻用药物制剂和使用方法 | |
| WO2001001978A1 (fr) | Compositions de medicaments servant a prevenir ou a traiter la myocardite virale | |
| KR20140074270A (ko) | 조합 als 치료법 | |
| CA2313270A1 (en) | Use of deferiprone in treating and preventing iron-induced cardiac disease | |
| JPWO2021216385A5 (https=) | ||
| JP2002255816A (ja) | 風邪治療用組成物 | |
| US5011841A (en) | Treatment of depression | |
| WO2025167739A1 (zh) | 化合物在制备预防和/或治疗高原病的药物中的应用 | |
| Vardas et al. | Amiodarone for the restoration of sinus rhythm in patients with atrial fibrillation | |
| JP5241127B2 (ja) | 鎮痛用組成物 | |
| CN115867288A (zh) | 用于治疗呼吸系统病症的组合物 | |
| JPWO2023043999A5 (https=) | ||
| JPS62267227A (ja) | 血中尿酸濃度の低下用医薬 | |
| JP2006508993A5 (https=) | ||
| US20070244102A1 (en) | Combination of Dermaciclane and Opoids as Analgesics | |
| IL312456A (en) | Treatment of major depressive disorder | |
| TW202220645A (zh) | 用於治療瘧疾的固定劑量組合藥物 | |
| US20250082677A1 (en) | Long covid medication and method of treatment | |
| JP2001089375A (ja) | 感冒用組成物 |